UPitt Alliance with Clinical Data Could Yield IP Related to PGx Response to mAb Cancer Therapies

The collaboration has the potential to generate new IP surrounding the role FCGR variants play in predicting therapeutic response to IgG1 treatments in a variety of cancers and other diseases – IP in which the University of Pittsburgh would own a stake.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register quickly here for free access.